Article

Wavefront-guided LASIK helpful tool for residual myopia

Stanford, CA-Wavefront-guided LASIK re-treatment procedures with the VISX CustomVue platform (VISX/Advanced Medical Optics [AMO]) seem to be effective, predictable, and safe in eyes with residual myopia using Fourier-based treatment software, reported Gloria Wang, MD.

Dr. Wang, chief resident at Stanford University, Stanford, CA, and colleague Edward Manche, MD, conducted a retrospective study in which they evaluated the CustomVue system and the effects of higher-order root mean square (RMS) values preoperatively and postoperatively.

Dr. Manche performed all surgeries using the VISX S4 excimer laser (VISX/ AMO) to treat patients who had previously undergone LASIK.

The mean preoperative spherical equivalent was –0.79 ± 0.50 D (range, –2.37 to 0.75 D). Three months after the enhancement surgery, the spherical equivalent decreased to –0.31 ± 0.36 D (range, –0.875 to +0.75 D), Dr. Wang reported.

No complications occurred. Of the 59 eyes, 57 eyes had been followed for 1 month and 31 eyes had 3 months of follow-up.

As expected, there was a decrease in the amount of myopia at 1 and 3 months postoperatively, with no significant difference between the two time points, Dr. Wang pointed out.

"The efficacy of the procedure was excellent; at 3 months postoperatively, 81% of eyes had 20/20 or better uncorrected visual acuity (UCVA) and 32% of eyes had 20/16 or better UCVA," Dr. Wang said. "The predictability was also excellent. All eyes were within 1 D of the target correction at the 3-month examination, and 81% of the eyes were within 0.5 D of the attempted correction at 3 months."

No eyes lost more than one line of best-corrected visual acuity (BCVA). Most eyes gained lines of BCVA 1 and 3 months after the enhancement procedure.

The analysis of higher-order aberrations showed that there was a decrease in the preoperative RMS from 0.39 ± 0.18 μm (range, 0.14 to 0.97 μm) to 0.35 ± 0.16 μm (range, 0.07 to 0.74 μm) 3 months after the enhancement. A reduction in coma was also observed from 0.22 μm preoperatively to 0.18 μm at the 3-month visit. The trefoil values were similar preoperatively and postoperatively at 0.13 μm and 0.12 μm, respectively. The spherical aberration decreased from 0.19 D preoperatively to 0.14 D at 3 months. No complications developed intraoperatively or postoperatively and there were no cases of epithelial ingrowth.

"Our results showed that the VISX CustomVue wavefront-guided re-treatment using Fourier-based treatment software in eyes that had undergone a previous LASIK procedure is effective, predictable, and safe for patients with residual myopia and compound myopic astigmatism," Dr. Wang said. "Analysis of higher-order RMS and aberrations showed a decreasing trend over time."

She noted, however, that longer follow-up is necessary to assess the stability of the refraction.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.